Acquired Orphan Blood Diseases Therapeutics Market Report 2024-2032

IMARC Group's report titled " Acquired Orphan Blood Diseases Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032", offers a comprehensive analysis of the industry, which comprises insights on the global acquired orphan blood diseases therapeutics market growth. The global market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market/requestsample

Factors Affecting the Growth of the Acquired Orphan Blood Diseases Therapeutics Industry:

• Rising Prevalence of Acquired Orphan Blood Diseases:

The increasing prevalence of acquired orphan blood diseases (AOBD) among the masses across the globe is contributing to the growth of the market. In addition, the increasing awareness among individuals about the importance of early disease diagnostics is impelling the market growth. Besides this, the growing demand for improved diagnostic techniques for accurate results is offering a positive market outlook. Furthermore, pharmaceutical companies are investing in research and development (R&D) activities to address the growing demand for personalized or targeted therapeutic approaches.

• Technological Advancements:

Innovations, such as gene editing, precision medicine, and targeted therapies, enable the development of more effective and tailored treatments. These advancements offer new hope to patients by improving treatment outcomes and reducing adverse effects. Additionally, technologies like high-throughput screening and bioinformatics accelerate drug discovery and development processes. Furthermore, advancements in biotechnology are leading to the development of biologic drugs and monoclonal antibodies targeting specific disease mechanisms involved in AOBD. These innovative therapies offer improved specificity and efficacy as compared to traditional treatments, such as immunosuppressive agents or blood products.  

• Increasing Healthcare Expenditure:

The rising adoption of AOBD therapeutics due to improving healthcare expenditure is supporting the market growth. Apart from this, governing agencies are allocating more resources to healthcare, which is impelling the market growth. Pharmaceutical companies benefit from this increased investment, enabling them to pursue innovative treatments for AOBD. Additionally, increased healthcare expenditure results in improved access to healthcare services, including diagnosis and treatment for rare diseases. Furthermore, the rising need for affordable therapeutics among patients is bolstering the market growth.

Leading Companies Operating in the Global Acquired Orphan Blood Diseases Therapeutics Industry:

• Alexion Pharmaceuticals Inc. (AstraZeneca plc)
• Amgen Inc.
• GSK plc
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co. Ltd.
• Rigel Pharmaceuticals Inc.
• Roche Holding AG
• Sanofi
• Takeda Pharmaceutical Company Limited

Acquired Orphan Blood Diseases Therapeutics Market Report Segmentation:

By Therapy:

• Recombinant Factor
• Immunoglobulin Infusion Therapy
• Activated Prothrombin Complex Concentrate
• Thrombopoietin Receptor Agonists
• Others

On the basis of the therapy, the market has been divided into recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists, and others.

By Disease Indication:

• Acquired Agranulocytosis
• Acquired Hemophilia
• Acquired Von Willebrand Syndrome
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Myelodysplastic Syndrome
• Others

Acquired hemophilia holds the biggest market share, which can be attributed to the rising utilization of specialized therapies, such as recombinant factor VIII inhibitors and immune-suppressive agents.  

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Hospital pharmacy accounts for the largest market share due to the wide availability of products in one place.

Regional Insights:

• North America: (United States, Canada)
• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America: (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys a leading position in the acquired orphan blood diseases therapeutics market on account of the presence of highly developed healthcare infrastructure, including advanced medical facilities, research institutions, and pharmaceutical companies.   

Global Acquired Orphan Blood Diseases Therapeutics Market Trends:

Governing agencies of various countries are incentivizing pharmaceutical companies to invest in AOBD therapeutics, which is supporting the growth of the market. In addition, orphan drug status provides benefits, such as market exclusivity, tax credits, and regulatory fee waivers, making it financially viable for companies to develop treatments for rare diseases. Furthermore, expedited review processes accelerate the approval timeline, bringing life-saving therapies to patients more quickly. These regulatory incentives reduce barriers to entry, foster innovation, and encourage investment in R&D activities.  

Apart from this, collaborations between pharmaceutical companies, research institutions, and patient advocacy groups facilitate the discovery, development, and commercialization of novel therapies, which is impelling the market growth.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163